» Articles » PMID: 38990415

Bacteria Extracellular Vesicle As Nanopharmaceuticals for Versatile Biomedical Potential

Overview
Journal Nano Converg
Specialty Biotechnology
Date 2024 Jul 11
PMID 38990415
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteria extracellular vesicles (BEVs), characterized as the lipid bilayer membrane-surrounded nanoparticles filled with molecular cargo from parent cells, play fundamental roles in the bacteria growth and pathogenesis, as well as facilitating essential interaction between bacteria and host systems. Notably, benefiting from their unique biological functions, BEVs hold great promise as novel nanopharmaceuticals for diverse biomedical potential, attracting significant interest from both industry and academia. Typically, BEVs are evaluated as promising drug delivery platforms, on account of their intrinsic cell-targeting capability, ease of versatile cargo engineering, and capability to penetrate physiological barriers. Moreover, attributing to considerable intrinsic immunogenicity, BEVs are able to interact with the host immune system to boost immunotherapy as the novel nanovaccine against a wide range of diseases. Towards these significant directions, in this review, we elucidate the nature of BEVs and their role in activating host immune response for a better understanding of BEV-based nanopharmaceuticals' development. Additionally, we also systematically summarize recent advances in BEVs for achieving the target delivery of genetic material, therapeutic agents, and functional materials. Furthermore, vaccination strategies using BEVs are carefully covered, illustrating their flexible therapeutic potential in combating bacterial infections, viral infections, and cancer. Finally, the current hurdles and further outlook of these BEV-based nanopharmaceuticals will also be provided.

Citing Articles

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.


Review on bacterial outer membrane vesicles: structure, vesicle formation, separation and biotechnological applications.

Zhao X, Wei Y, Bu Y, Ren X, Dong Z Microb Cell Fact. 2025; 24(1):27.

PMID: 39833809 PMC: 11749425. DOI: 10.1186/s12934-025-02653-9.


Pathogenic mechanisms and potential applications of extracellular vesicles from periodontal pathogens in periodontitis.

Zhang R, Li G, Wu Y, Wang X, Luan Q Front Immunol. 2025; 15():1513983.

PMID: 39759521 PMC: 11695242. DOI: 10.3389/fimmu.2024.1513983.


Manganese oxide nanomaterials: bridging synthesis and therapeutic innovations for cancer treatment.

Balwe S, Moon D, Hong M, Song J Nano Converg. 2024; 11(1):48.

PMID: 39604693 PMC: 11602914. DOI: 10.1186/s40580-024-00456-z.

References
1.
McClure E, Oliva Chavez A, Shaw D, Carlyon J, Ganta R, Noh S . Engineering of obligate intracellular bacteria: progress, challenges and paradigms. Nat Rev Microbiol. 2017; 15(9):544-558. PMC: 5557331. DOI: 10.1038/nrmicro.2017.59. View

2.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

3.
Rollier C, Dold C, Marsay L, Linder A, Green C, Sadarangani M . Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. mSphere. 2022; 7(1):e0067421. PMC: 8791392. DOI: 10.1128/msphere.00674-21. View

4.
Ren E, Wang Y, Liang T, Zheng H, Shi J, Cheng Z . Local Drug Delivery Techniques for Triggering Immunogenic Cell Death. Small Methods. 2023; 7(9):e2300347. DOI: 10.1002/smtd.202300347. View

5.
Allen E, Lempke S, Miller M, Bush D, Braswell B, Estes C . Effect of extracellular vesicles from S. aureus-challenged human neutrophils on macrophages. J Leukoc Biol. 2020; 108(6):1841-1850. PMC: 7686018. DOI: 10.1002/JLB.3AB0320-156R. View